Search results for "COSTS"

showing 10 items of 332 documents

Measuring the wastewater treatment plants productivity change: Comparison of the Luenberger and Luenberger-Hicks-Moorsteen Productivity Indicators

2019

Abstract It is essential to assess the productivity of wastewater treatment plants (WWTPs) to improve their economic and technical performance over time. In doing so, reliable indexes should be used to avoid biased conclusions leading to unsuccessful policy and managerial measures. Ratio-based indexes are typically employed, but are infeasible when any of the variables are equal or close to zero. To overcome this limitation, this paper presents the innovative approach of applying and comparing two difference-based productivity indicators, Luenberger (LPI) and Luenberger-Hicks-Moorsteen (LHMPI), to evaluate how productivity changes in a sample of WWTPs. Because the LHMPI is an additively com…

PollutantProductivity changeRenewable Energy Sustainability and the Environment020209 energyStrategy and Management05 social sciencesSample (statistics)02 engineering and technologyBuilding and ConstructionIndustrial and Manufacturing EngineeringTechnical performanceWastewater050501 criminology0202 electrical engineering electronic engineering information engineeringEconometricsEnvironmental scienceSewage treatmentOperational costsProductivity0505 lawGeneral Environmental ScienceJournal of Cleaner Production
researchProduct

Entry and exit in a vertically differentiated industry

2011

This paper presents a duopoly model of firm rivalry in a vertically differentiated industry when market dynamics is explicitly accounted for. It shows how the interplay between demand (degree of product differentiation, demand elasticity) and cost (fixed and quality costs) factors determine firms’ relative strength when quality is irreversible. The main strategic choices are product quality, price and the timing of entry and exit. Further, firms incur sunk quality costs at time of entry and operating fixed costs of maintaining quality. Although the low quality firm may outlast its rival in the declining phase, both firms wish to be the “quality leader”.

Price elasticity of demandEconomics and EconometricsComputingMilieux_THECOMPUTINGPROFESSIONmedia_common.quotation_subjectProduct differentiationProduct (business)Microeconomicsjel:L11entry exit vertical product differentiationjel:L13Quality (business)BusinessFixed costQuality costsDuopolyRivalryIndustrial organizationmedia_commonActa Oeconomica
researchProduct

Bringing strategy back into financial systems of performance measurement: integrating EVA and PBC

2012

This paper proposes a performance and cost measurement system that integrates the Economic Value Added criteria (EVA) with Process Based Costing (PBC). The EVA-PBC methodology allows us to implement the EVA management logic non only at the firm level, but also at lower levels of the organization. We discuss the role of EVA-PBC methodology in bringing strategy back into financial performance measures.

ProcessesEVA; Processes; Capital Costs; Corporate Strategy; Business Strategy;EVAPerformance measurementBusiness StrategySettore SECS-P/08 - Economia e Gestione delle ImpresePBCEVA; Processes; Capital Costs; Corporate Strategy; Business StrategyCapital CostsCorporate Strategy
researchProduct

Evaluation économique de la prématurité : une première année de vie aux enjeux majeurs : le cas de la France

2016

This thesis focuses on a first economic assessment of prematurity in France. Prematurity is defined as occurring before 37 weeks of gestation. It is increasing in France and worldwide. If the issues of public health are already well identified, medical care and collective choices concerning prematurity matters also involve significant economic challenges. The first part of this thesis attempts to present the public health issues of prematurity and highlights the remaining efforts required to provide prevention in France. It then considers economic issues on the use of socially fairer resources dedicated to perinatal health in a context where current health expenditure is rising. Assessment …

PréventionSNIIRAMCoûts extrahospitaliersGestational ageAnalyse économique[SHS.ECO]Humanities and Social Sciences/Economics and FinanceCoûts hospitaliersEconomic analysesAge gestationnel[ SHS.ECO ] Humanities and Social Sciences/Economies and financesNon-hospital costs[SHS.ECO] Humanities and Social Sciences/Economics and FinanceHospital costsPrematurityPrématurité
researchProduct

The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design.

2021

Up to 80% of first-episode psychosis patients suffer a relapse within five years of the remission. Relapse should be an important focus of prevention given the potential harm to the patient and family. It threatens to disrupt their psychosocial recovery, increases the risk of resistance to treatment and has been associated with greater direct and indirect costs for society. Based on a previous project entitled "Genotype-phenotype and environment. Application to a predictive model in first psychotic episodes" (PEPs Project), the project "Clinical and neurobiological determinants of second episodes of schizophrenia. Longitudinal study of first episode of psychosis" was designed, also known as…

PsychosisLongitudinal studymedicine.medical_specialtyIndirect costs03 medical and health sciences0302 clinical medicineRecurrenceIntervention (counseling)medicineHumansLongitudinal StudiesPsychiatryFirst episodebusiness.industryNeuropsychologyGeneral Medicinemedicine.disease030227 psychiatryPsychiatry and Mental healthPsychotic DisordersSchizophreniaSchizophreniabusinessPsychosocial030217 neurology & neurosurgeryFollow-Up StudiesRevista de psiquiatria y salud mental
researchProduct

Economic evaluation of sublingual immunotherapy vs. symptomatic treatment in allergic asthma.

2009

Background The worldwide increased prevalence of allergic diseases, and especially of respiratory allergy, is paralleled by increased health costs. This requires consideration of the cost to efficacy ratio of the available treatment to identify the optimal choice. Objective To compare the different economic relevance, over a long evaluation time, of symptomatic pharmacologic therapy and sublingual immunotherapy (SLIT) in patients with allergic asthma. Methods Seventy patients with perennial allergic asthma, sensitized to dust mites, were enrolled; 50 of these patients were treated with SLIT against house dust mites and 20 were treated with symptomatic drugs. The patients were evaluated for …

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyAllergyAdolescentCost-Benefit AnalysisImmunologyPopulationAdministration SublingualFollow-Up StudieSublingual administrationDrug TherapyImmunopathologyInternal medicinemedicineImmunology and AllergyHumansCost-Benefit AnalysieducationChildAsthmaeducation.field_of_studyDrug Therapy; Combined Modality Therapy; Immunotherapy; Humans; Asthma; Child; Health Care Costs; Cost-Benefit Analysis; Adult; Middle Aged; Follow-Up Studies; Adolescent; Administration Sublingual; Male; Femalebusiness.industryRespiratory diseaseHealth Care CostsMiddle Agedmedicine.diseaseSlitCombined Modality TherapyAsthmaSurgeryHealth Care CostObservational studyFemaleImmunotherapybusinessHumanFollow-Up StudiesAnnals of allergy, asthmaimmunology : official publication of the American College of Allergy, Asthma,Immunology
researchProduct

Economic costs associated with acute attacks and long-term management of hereditary angioedema.

2010

Background Hereditary angioedema (HAE) is a rare autosomal dominant disorder characterized by recurrent acute attacks of swelling of the larynx, abdomen, and periphery. Objective To assess the economic burden associated with acute attacks and long-term management of HAE. Methods Burden was assessed via a Web-based survey of HAE patients (≥18 years old) that solicited information on attack characterization, short-term treatment, long-term disease management, impact on work, and patient costs. A standardized instrument, the Work Productivity and Activity Impairment questionnaire, was included to assess impact on work productivity. Standard medical costs and US average wage costs were assigned…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyEmergency Medical Servicesmedia_common.quotation_subjectImmunologyWageDrug CostsIndirect costsCost of IllnessEconomic costSurveys and QuestionnairesLong term managementmedicineImmunology and AllergyHumansDisease management (health)Hospital CostsProductivityhealth care economics and organizationsmedia_commonbusiness.industryAngioedemas HereditaryEmergency departmentHealth Care Costsmedicine.diseaseHospitalizationHealth Care SurveysEmergency medicineHereditary angioedemaAcute DiseasePhysical therapyFemalebusinessAnnals of allergy, asthmaimmunology : official publication of the American College of Allergy, Asthma,Immunology
researchProduct

Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study.

2007

Introduction This study's aim was to assess economic data regarding the home assistance burden for advanced non-small cell lung cancer (NSCLC) patients in Italy. Patients and Methods One hundred four NSCLC patients in second-line chemotherapy (2LC) or in supportive therapy (ST) were enrolled in 18 Italian oncology departments and were observed for 3 months. The main caregiver's workload was assessed monthly by a task scale; other caregivers' activities were also registered. Eastern Cooperative Oncology Group performance status was assessed by physicians, and patients completed the Lung Cancer Symptoms (LCS) subscale. Formal caregiving time was valued according to market prices; informal car…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyLung NeoplasmsHome Nursingmedia_common.quotation_subjectAntineoplastic Agentscaregiving burden in advanced non-small cell lung cancerNSCLCQuality of lifeCost of IllnessCarcinoma Non-Small-Cell LungmedicineHumansLung cancermedia_commonAgedAged 80 and overbusiness.industrySocial SupportWorkloadAssistance burdenHealth Care CostsMiddle Agedmedicine.diseaseOncologyCaregiversItalySocioeconomic FactorsInformal caregivingSpouseSupportive psychotherapyScale (social sciences)Family medicinePhysical therapyCosts and Cost AnalysisQuality of LifeFemaleHabitNon small cellbusiness
researchProduct

Healthcare costs of the SATisfaction and adherence to COPD treatment (SAT)study follow-up

2019

Abstract Background Chronic obstructive pulmonary disease (COPD) is characterised by recurring exacerbations. We estimated the costs of healthcare resources for COPD management funded by the Italian National Healthcare Service (INHS) for one year. Methods We examined the demographic, clinical, and economic variables at enrolment and follow-up visits (at 6 and 12 months) of COPD patients participating in the SAT study and referred to 20 Italian pulmonary centres with different institutional characteristics. Costs were expressed in Euro (€) 2018. A random effects log-linear panel regression model was performed to predict the average cost per patient. Results Most of the centres were public in…

Pulmonary and Respiratory MedicineAdultmedicine.medical_specialtyCost-Benefit AnalysisSocio-culturaleMuscarinic AntagonistsPersonal SatisfactionSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineHealth careMedicineHumansCOPD management Econometric model Healthcare costs030212 general & internal medicineAdrenergic beta-2 Receptor AgonistsAverage costAgedAged 80 and overCOPDbiologyCOPD management; Econometric model; Healthcare costsbusiness.industryCOPD managementOxygen Inhalation TherapyRegression analysisHealth Care CostsLamaMiddle AgedHealthcare costsbiology.organism_classificationmedicine.diseaseRandom effects modelBronchodilator AgentsPatient Care ManagementRespiratory Function TestsEconometric model030228 respiratory systemItalyEmergency medicinePublic universityDisease ProgressionPatient ComplianceDrug Therapy CombinationbusinessPanel dataFollow-Up Studies
researchProduct

The whole story: treatment outcomes with SymbicortS

2002

Asthma is a chronic inflammatory disorder of the airways that has a considerable socioeconomic impact. Asthma management guidelines have been introduced to help provide better long-term control of asthma. Although recommended guidelines may increase the direct medication costs, the overall direct costs of asthma may be reduced due to fewer exacerbations. In addition, indirect costs due to lost productivity and mortality are reduced and patients have an improved quality of life. Inhaled corticosteroids are first-line therapy in the treatment of persistent asthma. Against this background, we have assessed the cost-effectiveness of Symbicort (budesonide and formoterol in a single inhaler), a t…

Pulmonary and Respiratory MedicineBudesonidemedicine.medical_specialtybusiness.industrymedicine.drug_classCost effectivenessInhalermedicine.diseaserespiratory tract diseasesIndirect costsQuality of lifeimmune system diseasesBronchodilatormedicineFormoterolIntensive care medicinebusinessAsthmamedicine.drugRespiratory Medicine
researchProduct